🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📊 Breaking! FLAME trial 10-yr results show focal boost to MRI-visible tumors significantly improves outcomes in intermediate/high-risk prostate cancer: • bDFS: 86% vs 71% (HR 0.40, p<0.0001) • DFS: 81% vs 66% (p<0.001) #ESTRO25 ESTRO

Congrats Ethan Ludmir MD and Chad Tang, MD for this publication's recognition as a recipient of the MD Anderson Cancer Center Excellence in Science Award. #endcancer #radonc ascopubs.org/doi/10.1200/JC…

💉Three IL-23p19 inhibitors are set to shake up the #IBD market, challenging J&J Innovative Medicine’s #Stelara and its wave of #biosimilars “The choice of IL-23 agent hinges on accessibility, not just access...” — Dr. Stephen B. Hanauer, MD of Northwestern Medicine Game on 💥 bit.ly/4dls9vK

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats Declan Murphy marlon perera + team European Association of Urology (EAU)! ➡️link shorturl.at/unfn5

We couldn't think of a more important & timely discussion on #ClinicalTrialsDay. Our patient voices are what makes our research move the needle in #cancer care. Today, we share our discussion w/ patient advocate Tambre Leighn, MA, CPC she/her. New episode: nrgoncology.org/Podcast #CTD2025 ACRP - Assoc. of Clinical Research Profession

Excited to share our latest work, now out in European Urology! We followed >166k prostate cancer survivors (1999–2019) using SEER-Medicare. RP+EBRT had the highest risk of urinary adverse events. EBRT surpassed RP at 10 yrs (with BT) & 14 yrs (alone). authors.elsevier.com/sd/article/S03…

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Who would have thought - a low carb high fat (LCHF) diet is bad for cholesterol levels and cardiovascular disease 🤦🏻‍♂️

More data against concurrent IO and XRT Journal of Clinical Oncology. Phase II study of concurrent pembrolizumab + chemoradiation for H&N SCC versus sequential CRT followed by pembro. Sequential had superior PFS and fewer immunosuppressive changes on serial biopsy. ascopubs.org/doi/10.1200/JC…

From #ASCO25: Amalia Stefanou, MD (Amalia Stefanou MD) shares how an APP-first care model boosted access for GI cancer patients and streamlined their path to treatment. #MoffittASCO25

Join Ben Creelan, MD, (Ben Creelan, MD) as he shares advances in immunotherapy for advanced non-small cell lung cancer being presented at #ASCO25! Read more: meetings.asco.org/2025-asco-annu… #MoffittASCO25 ASCO #NSCLC

Terrific work by Alexander Sherry and wonderful colleagues including CSO friends, w simultaneous pub in JAMA Oncology jamanetwork.com/journals/jamao… Pavlos Msaouel Fumiko Ladd Chino, MD, FASCO Dr. Nina Niu Sanford Bishal Gyawali, MD, PhD, FASCO Joseph Abi Jaoude Ramez Kouzy, MD

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

Mayo Clinic - wow what teamwork! This place just oozes good culture! For a busy clinical facing-practice; so impressed with working environment. No wonder the staff love working here! Thanks for having me as visiting prof 🙏🏽🙏🏽

We are supportive of the Gerald E. Connolly Esophageal Cancer Awareness Act of 2025 and are pleased to hear the House passed it by voice vote. This bill references AGA screening guidelines in the findings and requires a GAO study of esophageal cancer costs.

This is a step in the right direction. It marks the first time there has been legislation devoted to esophageal cancer and it will provide useful data.

Drew Moghanaki “possibility VALOR phIII RCT of surgery vs SABR will show no difference in stage I #lungcancer” #radonc #SABR2025 🇨🇦 🟰several studies showing no diff ⬇️ trends for surgery in 🇺🇸 🤔 sampling LNs in solid dom GGO not needed ⚖️ ?benefit of lobectomy nasser altorki

This is very important for patients to be aware of a completely non-invasive option for early stage lung cancer that in RCTs has at least similar outcomes to undergoing thoracic surgery. Hopefully National Comprehensive Cancer Network (NCCN) NSCLC panel can revisit this. Great for patients to have options and seek

It’s time to remove the designation of “unresectable” or “inoperable” when considering the option of radiotherapy for people with lung cancer. nejm.org/doi/full/10.10…